CICC Assists Viva Biotech in Follow-on Placing as Leading Placing Agent
On July 3, 2020, CICC, as the lead placing agent and settlement agent, assisted Viva Biotech (the Company, 1873. HK) to issue 130 million new shares (the Placement), with a price of HK $8.15 and offering size of about US$137 million.
Viva Biotech was established in 2008. It operates a leading structure-based, integrated drug discovery platform, and is the first company listing on HKEX with the main business of innovative “CRO + incubation” model. Viva Biotech provides structure-based drug discovery services to over 438 biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. On this basis, the Company innovatively combines the conventional cash-for-service (CFS) model and the unique equity-for-service (EFS) model. With the combination of CFS and EFS model, Viva Biotech has achieved the leap from CRO business to the trillion-dollar pharmaceutical market and become a cradle for promising biotechnology start-ups.
CICC initiated the project and took the lead in each work line to ensure the overall progress of the execution. As the leading placing agent, CICC offered accurate pricing guidance. In the complex domestic and foreign market environment, based on accurate judgment of the market environment and timely grasp of the issuance window, CICC advised the Company to launch the issuance immediately after the close of the pricing day, leading to a successful issuance result featuring both satisfactory price and volume.
CICC provides a full spectrum of services throughout business lifecycle for Viva Biotech. Since CICC has served Viva Biotech, the client’s market value has increased from about US $500 million to US $1.9 billion, with an increase of nearly 300%. Since 2018, CICC has provided full spectrum capital market services for Viva Biotech, including the pre IPO Financing in 2018, the Hong Kong IPO in 2019, the issuance of convertible bonds in 2020 and this Placement. The total deal value that CICC assisted is nearly US$600 million. CICC successfully ensured the offering and was highly recognized by the Company, reflecting the absolute leading edge and independent leading ability of CICC in full spectrum of capital market services and healthcare industry.
As a leading investment bank with “Chinese Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and promoting global business development.